

(<https://www.aphadruginfoline.com>)

[Home](#) > Indication added for bipolar I disorder

Generic Name:

Aripiprazole

Trade Name:

Abilify

Company:

Bristol-Myers Squibb

Notes:

Approval of this [agent](#) was based on data from a 52-week maintenance trial with 337 patients with bipolar I disorder. Patients on combination therapy had fewer mood events (n = 25) compared with those on either lithium or valproate alone (n = 43). This difference was primarily attributed to a reduction in manic episodes (7 vs. 19), not depressive episodes (14 vs. 18). Tremor occurred more frequently with combination therapy (6% vs. 2.4%).

Medication Monitor Categories:

[Supplemental Approvals](#)

Use:

Maintenance treatment of bipolar I disorder as an adjunct to either lithium or valproate

Source URL: <https://www.aphadruginfoline.com/supplemental-approvals/indication-added-bipolar-i-disorder>